Markets:

Overview

News

Currencies

International

Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

0.1070 -0.0300 (-21.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

June 29, 2023

We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today!

Via InvestorPlace

BioXcel CEO Vimal Mehta Says This Alzheimer's News Is A 'Huge Win For Society' ↗

June 29, 2023

The company hopes to soon gain approval to treat patients with agitation due to Alzheimer's disease.

Via Investor's Business Daily

3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally ↗

June 15, 2023

If you can’t stand a dull day at the trading desk, these short-squeeze stocks to buy could spike your blood pressure and your portfolio.

Via InvestorPlace

Goldman Sachs Maintains Neutral Rating for BioXcel Therapeutics: Here's What You Need To Know ↗

May 26, 2023

Via Benzinga

Where BioXcel Therapeutics Stands With Analysts ↗

May 26, 2023

Via Benzinga

Why Shares of BioXcel Therapeutics Are Dropping Thursday ↗

May 25, 2023

A trial for one of the company's therapies didn't meet its primary endpoint.

Via The Motley Fool

Looking Into BioXcel Therapeutics's Return On Capital Employed ↗

May 22, 2023

Via Benzinga

The Latest Analyst Ratings for BioXcel Therapeutics ↗

May 09, 2023

Via Benzinga

Why BioXcel Therapeutics Stock Marched Higher Today ↗

May 08, 2023

The biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 25, 2023

Via Benzinga

Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 25, 2023

Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR.

Via Benzinga

BioXcel Therapeutics's Earnings Outlook ↗

May 05, 2023

Via Benzinga

6 Analysts Have This to Say About BioXcel Therapeutics ↗

March 10, 2023

Via Benzinga

Earnings Preview: BioXcel Therapeutics ↗

March 08, 2023

Via Benzinga

Expert Ratings for BioXcel Therapeutics ↗

February 08, 2023

Via Benzinga

BioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation ↗

May 25, 2023

Via Benzinga

BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain ↗

May 25, 2023

The company is hoping to double its market opportunity. But that looks less certain.

Via Investor's Business Daily

BioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression Treatment ↗

May 16, 2023

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced topline data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film, for agitation associated with...

Via Benzinga

Why These 3 Nasdaq Stocks Were Glowing Green This Week ↗

May 11, 2023

These three biopharmaceutical stocks rocketed higher this week.

Via The Motley Fool

BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues ↗

May 08, 2023

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported first-quarter FY23 revenues of $206,000,

Via Benzinga

Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite. ↗

May 08, 2023

Axsome shares are nearing a breakout point. But BioXcel crumbled on its report.

Via Investor's Business Daily

Why BioXCel Therapeutics Stock Jumped This Week ↗

December 15, 2022

A couple of analysts recently upgraded their views on the biotech stock.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 08, 2023

Via Benzinga

The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO ↗

May 04, 2023

This company is hoping to execute for a second time on its moonshot goal.

Via Investor's Business Daily

Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 21, 2023

Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023 ↗

March 10, 2023

Via Benzinga

BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype ↗

February 14, 2023

Via Benzinga

Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023 ↗

February 08, 2023

Via Benzinga

ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption' (Not Just At Google) ↗

February 03, 2023

"A lot of disruption" may be coming soon to a host of industries. Google may be at risk.

Via Investor's Business Daily

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.